Journal
BIOCONJUGATE CHEMISTRY
Volume 23, Issue 5, Pages 1029-1039Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bc300037w
Keywords
-
Categories
Funding
- King's College London-UCL Comprehensive Cancer Imaging Centre
- Cancer Research UK
- EPSRC [WT 088641/Z/09/Z]
- MRC
- DoH (UK)
- Cancer Council Victoria
- State Government of Victoria
- Australian Research Council
- Wellcome Trust
- National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre
- King's College London
- King's College Hospital NHS Foundation Trust
- Guy's and St. Thomas' Charity
- Centre of Excellence in Medical Engineering
- National Institute for Health Research
- Biomedical Research Centre
- Harris studentship
Ask authors/readers for more resources
High radiolabeling efficiency, preferably to high specific activity, and good stability of the radioimmunoconjugate are essential features for a successful immunoconjugate for imaging or therapy. In this study, the radiolabeling efficiency, in vitro stability, and biodistribution of immunoconjugates with eight different bifunctional chelators labeled with Cu-64 were compared. The anti-CD20 antibody, rituximab, was conjugated to four macrocyclic bifunctional chelators (p-SCN-Bn-DOTA, p-SCN-Bn-Oxo-DO3A, p-SCN-NOTA, and p-SCN-PCTA), three DTPA derivatives (p-SCN-Bn-DTPA, p-SCN-CHX-A-DTPA, and ITC-2B3M-DTPA), and a macrobicyclic hexamine (sarcophagine) chelator (sar-CO2H) = (1-NH2-8-NHCO-(CH2)(3)CO2H)sar where sar = sarcophagine = 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane). Radiolabeling efficiency under various conditions, in vitro stability in serum at 37 degrees C, and in vivo biodistribution and imaging in normal mice over 48 h were studied. All chelators except sar-CO2H were conjugated to rituximab by thiourea bond formation with an average of 4.9 +/- 0.9 chelators per antibody molecule. Sar-CO2H was conjugated to rituximab by amide bond formation with 0.5 chelators per antibody molecule. Efficiencies of Cu-64 radiolabeling were dependent on the concentration of immunoconjugate. Notably, the Cu-64-NOTA-rituximab conjugate demonstrated the highest radiochemical yield (95%) under very dilute conditions (31 nM NOTA-rituximab conjugate). Similarly, sar-CO-rituximab, containing 1/10th the number of chelators per antibody compared to that of other conjugates, retained high labeling efficiency (98%) at an antibody concentration of 250 nM. In contrast to the radioimmunoconjugates containing DTPA derivatives, which demonstrated poor serum stability, all macrocyclic radioimmunoconjugates were very stable in serum with <6% dissociation of Cu-64 over 48 h. In vivo biodistribution profiles in normal female Balb/C mice were similar for all the macrocyclic radioimmunoconjugates with most of the activity remaining in the blood pool up to 48 h. While all the macrocyclic bifunctional chelators are suitable for molecular imaging using Cu-64-labeled antibody conjugates, NOTA and sar-CO2H show significant advantages over the others in that they can be radiolabeled rapidly at room temperature, under dilute conditions, resulting in high specific activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available